According to the risk score model we built, among BLCA patients, those with high expression levels of ESD, GALK1, GLCE, HSPG2, HYAL3, MECR, NUP188, PPP2CB, and TPST1 had a poorer prognosis than those with low expression. This evidence concerns the gene GLCE and bladder transitional cell carcinoma.